Evolving mEGFR 2+ L therapy

返回会议原文

返回会议

Jose Fernando Moura, PhD· @FernandoOnco · X·2026-10-26 17:06· 5 小时前评分70

izalontamab

正文 · 原文

Evolving mEGFR 2+ L therapy
Two trials, two differents ADCs 🇨🇳

Izalontamab-brengitecan bi-specific (HER3xEGFR), DAR 8
Ruzaltatug-rezetecan (HER3), DAR 4

Strong signals in PFS
@myESMO #ESMO26

25 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要

2575PNCT06838273 NCT06838273 NCT06838273按 NSCLC, locally advanced 对上

Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)

https://esmocongress.esmo.org

LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

来源：Jose Fernando Moura, PhD · x.com